Does viral serine proteinase inhibitor ( SERP-1 ) effectively decrease the incidence of graft vasculopathy in heterotopic heart allografts?
Treatment of allograft recipients with SERP-1 in combination with CsA early after transplantation significantly decreases the incidence of GVD when compared to grafts treated with only CsA. These results demonstrate the clinical potential for this novel serine protease inhibitor to prevent GVD in solid organ transplantation.
Tumor rupture was associated with decreased DSS and DRFS in stage III sarcomas. It also predicted early metastasis and directly impacted patient's survival. Additional procedures should be investigated to avoid tumor rupture.